An Exploratory Study on Gene Methylation Detection of Colorectal Cancer
1 other identifier
observational
450
1 country
1
Brief Summary
The goal of this exploration study is to evaluate the performance of a colorectal cancer (CRC) early screening model based on the DNA methylation technology platform. The study focuses on individuals over the age of 40 and aims to identify and verify methylation biomarkers for colorectal cancer using stool samples . The main question it aims to answer is: Can a DNA methylation-based model effectively detect colorectal cancer and adenoma in individuals over 40 using non-invasive stool samples? Participants will provide stool samples for methylation analysis. The study results will be used solely for internal product performance evaluation and optimization by the sponsor and will not be used for product registration or influence any clinical diagnosis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Dec 2024
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 24, 2024
CompletedFirst Submitted
Initial submission to the registry
June 13, 2025
CompletedFirst Posted
Study publicly available on registry
June 24, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 20, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
October 20, 2025
CompletedJune 29, 2025
June 1, 2025
8 months
June 13, 2025
June 25, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
human stool gene methylation
The core of the study is to detect the methylation levels of three genes in human stool samples. These three genes are SDC2, COL4A2, and C9orf50. The procedure includes stool sample collection, stool nucleic acid extraction, bisulfite conversion, and detection using the qMSP (quantitative Methylation-Specific PCR) method.
2024.12-2025.8
Interventions
This study does not require intervention trials
Eligibility Criteria
Hospital physical examination, outpatient, and inpatient patients;
You may qualify if:
- Sample Source: Hospital physical examination, outpatient, and inpatient patients;
- Patient Information: Patient information (such as age, hospital ID number, gender, clinical diagnosis, colonoscopy and pathology results) is traceable;
- Age Requirement: ≥ 40 years old;
- Sampling Time Requirement: Stool and plasma samples must be collected within 3 months prior to colonoscopy (stool samples are preferred).
You may not qualify if:
- Unclear Sample Collection Information: Samples with unclear collection time, or stool samples not collected within 3 months prior to colonoscopy, or samples with incomplete clinical information that cannot be traced;
- Non-compliance with Sample Requirements: Samples that do not meet the collection and storage requirements;
- History of Disease: Subjects with a history or treatment of colorectal cancer (CRC) or advanced precancerous lesions;
- Insufficient Sample Volume: Samples with insufficient volume that cannot meet the requirements of the assessment system testing;
- Hereditary Diseases: Subjects with a diagnosis or family history of the following diseases:Familial adenomatous polyposis (FAP), including attenuated FAP and Gardner syndrome;Hereditary nonpolyposis colorectal cancer syndrome (HNPCC or Lynch syndrome);Other hereditary cancer syndromes, including but not limited to Peutz-Jeghers syndrome, MYH-associated polyposis (MAP), Turcot syndrome (or Crail syndrome), Cowden syndrome, juvenile polyposis, neurofibromatosis, or familial proliferative polyposis (FAP);
- Inflammatory Bowel Disease (IBD): Subjects with a diagnosis or personal history of IBD, including chronic ulcerative colitis and/or Crohn's disease;
- Cronkhite-Canada Syndrome: Subjects with a diagnosis of Cronkhite-Canada syndrome.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Zhejiang Provincial People's Hospitallead
- Jinjiang Central Hospitalcollaborator
- Xilingol League Central Hospitalcollaborator
- Zybio Inc.collaborator
- Haining Central Hospitalcollaborator
- Tiantai County People's Hospitalcollaborator
- Xianju County People's Hospitalcollaborator
- Fuyang District People's Hospitalcollaborator
- Second Affiliated Hospital, School of Medicine, Zhejiang Universitycollaborator
Study Sites (1)
Zhejiang Provincial People's Hospital
Hangzhou, Zhejiang, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- associate senior doctor
Study Record Dates
First Submitted
June 13, 2025
First Posted
June 24, 2025
Study Start
December 24, 2024
Primary Completion
August 20, 2025
Study Completion
October 20, 2025
Last Updated
June 29, 2025
Record last verified: 2025-06
Data Sharing
- IPD Sharing
- Will not share